Latest Insider Transactions at Kymera Therapeutics, Inc. (KYMR)
This section provides a real-time view of insider transactions for Kymera Therapeutics, Inc. (KYMR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kymera Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kymera Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$122,500
$49.0 P/Share
|
|
Dec 02
2024
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$72,500
$29.55 P/Share
|
|
Sep 17
2024
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
13,500
-73.52%
|
$648,000
$48.25 P/Share
|
|
Sep 17
2024
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
13,500
+38.51%
|
$283,500
$21.87 P/Share
|
|
Aug 26
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$245,000
$49.1 P/Share
|
|
Aug 26
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$50,000
$10.34 P/Share
|
|
Aug 20
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1
|
$46
$46.41 P/Share
|
|
Jul 16
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
23,145
-10.27%
|
$1,041,525
$45.84 P/Share
|
|
Jul 16
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,145
+16.3%
|
$46,290
$2.08 P/Share
|
|
Jul 15
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
16,455
-14.67%
|
$740,475
$45.15 P/Share
|
|
Jul 15
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,455
+12.79%
|
$32,910
$2.08 P/Share
|
|
Jul 09
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
453,960
-1.87%
|
$16,796,520
$37.42 P/Share
|
|
Jul 01
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,773
+2.81%
|
$93,865
$5.33 P/Share
|
|
Jun 27
2024
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+12.92%
|
$50,000
$2.08 P/Share
|
|
Jun 18
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,413
+2.23%
|
$28,826
$2.08 P/Share
|
|
Jun 13
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
10,200
-0.2%
|
$346,800
$34.98 P/Share
|
|
Jun 12
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
16,740
-0.17%
|
$585,900
$35.68 P/Share
|
|
Jun 07
2024
|
Joanna Horobin |
SELL
Open market or private sale
|
Direct |
8,500
-62.86%
|
$272,000
$32.88 P/Share
|
|
Jun 07
2024
|
Joanna Horobin |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+50.0%
|
$17,000
$2.08 P/Share
|
|
May 23
2024
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,575
-5.51%
|
$87,550
$34.99 P/Share
|
|
Mar 15
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
71,764
-0.47%
|
$2,870,560
$40.39 P/Share
|
|
Mar 14
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
55,779
-0.36%
|
$2,231,160
$40.63 P/Share
|
|
Mar 13
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
139,255
-1.31%
|
$5,848,710
$42.51 P/Share
|
|
Mar 13
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
24,165
-1.42%
|
$1,014,930
$42.51 P/Share
|
|
Mar 13
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
115,090
-1.2%
|
$4,833,780
$42.51 P/Share
|
|
Mar 12
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
162,918
-1.49%
|
$6,842,556
$42.23 P/Share
|
|
Mar 12
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
28,271
-1.61%
|
$1,187,382
$42.23 P/Share
|
|
Mar 12
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
134,647
-1.37%
|
$5,655,174
$42.23 P/Share
|
|
Mar 11
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
51,184
-0.46%
|
$2,200,912
$43.09 P/Share
|
|
Mar 11
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Indirect |
8,882
-0.5%
|
$381,926
$43.09 P/Share
|
|
Mar 11
2024
|
Atlas Venture Fund X, L.P. |
SELL
Open market or private sale
|
Direct |
42,302
-0.43%
|
$1,818,986
$43.09 P/Share
|
|
Mar 04
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,344
-1.14%
|
$140,448
$42.35 P/Share
|
|
Mar 04
2024
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,934
-0.9%
|
$165,228
$42.35 P/Share
|
|
Mar 01
2024
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,375
+19.74%
|
-
|
|
Mar 01
2024
|
Ellen Chiniara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,755
+27.99%
|
-
|
|
Mar 01
2024
|
Jeremy G Chadwick Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,425
+22.31%
|
-
|
|
Mar 01
2024
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+17.6%
|
-
|
|
Feb 27
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
400
-0.53%
|
$18,000
$45.0 P/Share
|
|
Feb 27
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.53%
|
$800
$2.08 P/Share
|
|
Feb 21
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
4,385
-100.0%
|
$171,015
$39.05 P/Share
|
|
Feb 21
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
4,385
+50.0%
|
$43,850
$10.34 P/Share
|
|
Feb 20
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
615
-100.0%
|
$23,985
$39.07 P/Share
|
|
Feb 20
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
615
+50.0%
|
$6,150
$10.34 P/Share
|
|
Feb 09
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
46,137
-20.53%
|
$1,614,795
$35.74 P/Share
|
|
Feb 09
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,137
+27.63%
|
$92,274
$2.08 P/Share
|
|
Jan 23
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$300,000
$30.05 P/Share
|
|
Jan 23
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$100,000
$10.34 P/Share
|
|
Jan 04
2024
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,295
-8.79%
|
$72,490
$22.58 P/Share
|
|
Jan 02
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+1.44%
|
$18,000
$2.08 P/Share
|
|
Nov 03
2023
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
197,699
+3.64%
|
$2,767,786
$14.07 P/Share
|